Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

Figures & data

Table 1 Patient demographics

	Eligible patients N = 796 n (%)
Age (mean years ± SD)	69.4 ± 11.8
Gender
Male	311 (39)
Female	485 (61)
Race
Caucasian	610 (77)
African-American	110 (14)
Hispanic	39 (5)
Asian	31 (4)
Other	6 (1)
Diagnosis
Primary open-angle glaucoma	708 (89)
Ocular hypertension	77 (10)
Exfoliative glaucoma	8 (1)
Pigment dispersion glaucoma	3 (0.4)

Figure 1 Improvement in ocular surface disease index scores with travoprost BAK-free according to previous prostaglandin analog use. *p < 0.0001.

Figure 2 Improvement in ocular surface disease index scores with travoprost BAK-free according to baseline severity. *p < 0.0001.

Table 2 Patients with an OSDI score that improved by at least one level of severity

OSDI severity grouping (baseline)	Patients improved to normal [n (%)]	Patients improved to mild [n (%)]	Patients improved to moderate [n (%)]	Patients improved by at least 1 level [n (%)]
Mild (n = 112)	79 (70.5%)	N/A	N/A	79 (70.5%)
Moderate (n = 59)	21 (35.6%)	18 (30.5%)	N/A	39 (66.1%)
Severe (n = 64)	15 (23.4%)	21 (32.8%)	11 (17.2%)	47 (73.4%)
Mild + Moderate + Severe (n = 235)	115 (48.9%)	39 (16.6%)	11 (4.7%)	165 (70.2%)

Abbreviations: OSDI, Ocular Surface Disease Index.

Figure 3 Clinically significant improvement (≥9 points) in ocular surface disease index scores with travoprost BAK-free according to baseline severity.

Figure 4 Change in mean IOP with travoprost BAK-free according to previous prostaglandin analog use. *p < 0.0001.

Figure 5 Change in mean hyperemia scores with travoprost BAK-free according to previous prostaglandin analog use. *p < 0.0001.

Table 3 Ophthalmic adverse events with travoprost BAK-free

Description	n
Hyperemia	49
Change in visual acuity	28
Burning	14
Irritation	9

Adverse events with an incidence of at least 1%.

Table 4 Patient preference (per patient analysis)

Baseline prostaglandin analog	n	Preferred previous therapy	Preferred travoprost BAK-free	p-value
Latanoprost	476	25.4%	74.6%	<0.0001
Bimatoprost	215	32.6%	67.4%	<0.0001
Combined	691	27.6%	72.4%	<0.0001